

MARKOV MODELS FOR ACCUMULATING MUTATIONS

NIKO BEERENWINKEL AND SETH SULLIVANT

ABSTRACT. We introduce and analyze a waiting time model for the accumulation of genetic changes. The continuous time conjunctive Bayesian network is defined by a partially ordered set of mutations and by the rate of fixation of each mutation. The partial order encodes constraints on the order in which mutations can fixate in the population, shedding light on the mutational pathways underlying the evolutionary process. We study a censored version of the model and derive equations for an EM algorithm to perform maximum likelihood estimation of the model parameters. We also show how to select the maximum likelihood poset. The model is applied to genetic data from different cancers and from drug resistant HIV samples, indicating implications for diagnosis and treatment.

1. INTRODUCTION

The genetic progression of cancer is characterized by the accumulation of mutations in oncogenes and in tumor suppressor genes. Recent studies have shown that during the somatic evolution of cancer mutations in over 100 human genes are selected for, suggesting their beneficial effect on the growth of the cancer cell (Sjöblom et al., 2006).

In HIV infection, the virus acquires mutations in CTL epitopes that interfere with the immune response. This evolutionary process is specific for the genetic makeup of the infected host. Recently, a total of 478 CTL escape mutations have been identified in the HIV genome (Brumme et al., 2007).

Under drug treatment, HIV develops mutations that confer resistance to the applied drugs. Eventually, this evolutionary escape leads to therapy failure. More than 50 drug resistance-associated mutations are known in three different HIV proteins (Johnson et al., 2006).

These three evolutionary scenarios have in common that, for the population of individuals, several mutations are available which increase fitness. Adaption is therefore characterized by the accumulation of these beneficial mutations which are virtually non-reversible.

In this paper, we introduce a statistical model for the accumulation of genetic changes. The continuous time conjunctive Bayesian network (CT-CBN) is a continuous time Markov chain model, defined by a partially ordered set (poset) of advantageous mutations, and the rate of fixation for each mutation. The partial order encodes constraints on the succession in which mutations can occur and fixate in the population. We assume that the fixation times follow independent exponential distributions. The exponential waiting process for a mutation starts only when all predecessor mutations of that mutation in the poset have already occurred. The order constraints and waiting times reveal important information on the underlying biological process with implications for diagnosis and treatment.

The CT-CBN is a continuous time analogue of the discrete conjunctive Bayesian network (D-CBN) introduced by Beerenwinkel et al. (2006). The D-CBN was shown to have very desirable

statistical and algebraic properties (Beerenwinkel et al.). We argue that the continuous time CBN is the more natural model for the waiting process described above, and we explore the connection to the discrete CBN. A special case of the D-CBN, where the poset is a tree, is known as the oncogenetic or mutagenetic tree model (Desper et al., 1999; Beerenwinkel et al., 2005b,c). It has been applied to the somatic evolution of cancer (Radmacher et al., 2001; Rahnenführer et al., 2005) and to the evolution of drug resistance in HIV (Beerenwinkel et al., 2005a). The basic mutagenetic tree model has been extended to a mixture model (Beerenwinkel et al., 2005b) and to account for longitudinal data (Beerenwinkel and Drton, 2007).

A related tree model by von Heydebreck et al. (2004) represents the genetic changes at the leaves of the tree and regards the interior vertices as hidden events. Several authors have considered larger model classes, including general Bayesian networks (Simon et al., 2000; Deforche et al., 2006) and general Markov chain models on the state space of mutational patterns (Foulkes and DeGruttola, 2003; Hjelm et al., 2006). As compared to trees and posets, these models are more flexible in describing mutational pathways, but parameter estimation and model selection is considerably more difficult. In fact, the number of free parameters of these models is typically exponential in the number of mutations. By contrast, in the CT-CBN model, the number of free parameters equals the number of mutations. We demonstrate that parameter estimation and selection of an optimal poset can be performed efficiently for CT-CBNs. Thus, they provide an attractive framework for modeling the accumulation of mutations, especially if the number of mutations is moderate or large.

We formally define the CT-CBN in the next Section 2 and derive some basic properties of the model. The CT-CBN is an example of a regular exponential family with closed form maximum likelihood estimates (MLEs). In Section 3, we make precise the relation between the CT-CBN and the D-CBN. Section 4 deals with a censored version of the CT-CBN which is most relevant for observed data. The censored model lacks a closed form expression for the MLE, but has a natural EM algorithm for approximating maximum likelihood estimates. We apply our methods in Section 5 to genetic data from cancer cells and from drug resistant HI viruses. We close with a discussion in Section 6.

2. CONTINUOUS TIME CONJUNCTIVE BAYESIAN NETWORKS

In this section, we introduce and describe some of the basic properties of continuous time conjunctive Bayesian networks (CT-CBN). These models are continuous time Markov chain models on the distributive lattice of a poset. To begin, we review some background material from combinatorics. The relevant combinatorial material can be found in introductory sections of Beerenwinkel et al. (2006) and more detailed information is covered in Stanley (1999).

A partially ordered set (poset) is a set P with a transitive relation $\preceq$. In our models, the set P will be a set of genetic events, and the order relation $\preceq$ specifies partial information about the order in which these events must occur. The relation $p \prec q$ implies that event p happens before event q . The distributive lattice of order ideals of P , denoted by $J(P)$, consists of all subsets $S \subseteq P$, that are closed downward, i.e., $S \in J(P)$ if and only if, for all $q \in S$ and $p \prec q$, we have that $p \in S$. The order ideals of P correspond to the genotypes (or mutational patterns) that are compatible with the order constraints. We refer to $\emptyset \in J(P)$ as the wild type.




FIGURE 1. Running example.

Example 2.1. As a running example, consider the poset P on the four element set $[4] = \{1, 2, 3, 4\}$ subject to the order relations $1 \prec 3$, $2 \prec 3$, $2 \prec 4$. The distributive lattice $J(P)$ of order ideals of P consists of eight elements. Both sets are displayed in Figure 1.

Let P be a poset with ground set $[n]$. For each event $i \in P$, we define a random variable $Z_i \sim \text{Exp}(\lambda_i)$. Then we define the random variables X_i as

$$X_i = \max_{j \in \text{pa}(i)} \{X_j\} + Z_i, \quad i = 1, \dots, n.$$

Here $\text{pa}(i)$ is the set of all predecessors of event i in the poset P . The random variable X_i describes how long we have to wait until event i occurs assuming that we start at time zero with no events. Mutation i cannot occur until all the mutations preceding it in the partial order P have occurred. The family of joint distributions of X defined in this manner is the continuous time conjunctive Bayesian network (CT-CBN). It has state space $\mathbb{R}_{>0}^n$ consisting of vectors of waiting times and parameters $\lambda = (\lambda_1, \dots, \lambda_n) \in \mathbb{R}_{>0}^n$.

The probability density function associated to this model is easy to write down, given the recursive conditional nature of the distribution. The density function is

$$(1) \quad f_{P,\lambda}(t) = \prod_{i=1}^n \lambda_i \exp(-\lambda_i(t_i - \max_{j \in \text{pa}(i)} t_j)), \quad \text{if } t_i > \max_{j \in \text{pa}(i)} t_j \text{ for all } i \in [n],$$

and $f_{P,\lambda}(t) = 0$ otherwise. The CT-CBN is an example of a regular exponential family, with minimal sufficient statistic consisting of the vector of time differences $(t_i - \max_{j \in \text{pa}(i)} t_j)_{i \in [n]}$.

One instance of the random variable X is a sequence of times $T = (t_1, \dots, t_n)$ that satisfy the inequality relations implied by P , i.e., $t_i > \max_{j \in \text{pa}(i)} t_j$ for all $i \in [n]$. A set of times satisfying the indicated inequality constraints is *compatible* with the poset. Thus, the data for the model is a list of sequences of times $T_1, \dots, T_N$, where N is the number of observations.

Proposition 2.2. *Let P be a poset and $T_1, \dots, T_N$ be a collection of data. If any of the T_k are incompatible with the poset P , the maximum likelihood estimate does not exist (the likelihood function is identically zero). Otherwise, the maximum likelihood estimate of λ is given by*

$$\hat{\lambda}_i = \frac{N}{\sum_{k=1}^N (t_{ki} - \max_{j \in \text{pa}(i)} t_{kj})}, \quad i \in [n].$$

Proof. Suppose the data $T_1, \dots, T_N$ are compatible with the poset P . Then from Equation 1, the log-likelihood function is

$$\ell(\lambda_1, \dots, \lambda_n) = \sum_{k=1}^N \sum_{i=1}^n \left(\log \lambda_i - \lambda_i (t_{ki} - \max_{j \in \text{pa}(i)} t_{kj}) \right).$$

Differentiating with respect to λ_i yields the equations

$$\sum_{k=1}^N \left(\frac{1}{\lambda_i} - (t_{ki} - \max_{j \in \text{pa}(i)} t_{kj}) \right) = 0,$$

and the claimed formula follows by solving for λ_i . $\square$

Theorem 2.3. *Given data $T_1, \dots, T_N$, the maximum likelihood poset is the largest poset that is compatible with the data.*

Proof. Let $(P^1, \prec_1)$ and $(P^2, \prec_2)$ be two posets, both compatible with the data, such that P^1 is a refinement of P^2 (that is, every relation that holds in P^2 also holds in P^1). It suffices to show that the likelihood function evaluated at the MLE is larger for P^1 than P^2 , because this implies that adding relations compatible with the data increases the likelihood.

Denote the MLEs for P^1 and P^2 by $\hat{\lambda}^1$ and $\hat{\lambda}^2$, respectively. According to Proposition 2.2 these values are given by

$$\hat{\lambda}_i^l = \frac{N}{\sum_{k=1}^N (t_{ki} - \max_{j \in \text{pa}_l(i)} t_{kj})}.$$

It does not change the expression to replace $\text{pa}_l(i)$ with the set $\{j \in P^l : j \prec_l i \text{ in } P^l\}$. Since P^1 has more relations than P^2 , this implies that the maximum is taken over a strictly larger set, and thus $\hat{\lambda}_i^1 \geq \hat{\lambda}_i^2$ for all i .

However, the log-likelihood function evaluated at $\hat{\lambda}^l$ is

$$\begin{aligned} \ell_l(\hat{\lambda}^l | T) &= \sum_{k=1}^N \sum_{i=1}^n \left(\log \hat{\lambda}_i^l - \hat{\lambda}_i^l (t_{ki} - \max_{j \in \text{pa}_l(i)} t_{kj}) \right) \\ &= \sum_{i=1}^n \left(N \log \hat{\lambda}_i^l - \hat{\lambda}_i^l \sum_{k=1}^N (t_{ki} - \max_{j \in \text{pa}_l(i)} t_{kj}) \right) \\ &= \sum_{i=1}^n (N \log \hat{\lambda}_i^l - N). \end{aligned}$$

Since the logarithm is a monotone function, we deduce that $\ell_1(\hat{\lambda}^1 | T) \geq \ell_2(\hat{\lambda}^2 | T)$. $\square$

One of the most interesting quantities that we can compute with respect to the CT-CBN is the expected waiting time until a particular pattern $S \in J(P)$ is reached in the course of evolution. In other words, assuming that the parameters λ are known, we are asking how long it takes until a certain collection of genetic events have occurred. The expected waiting time is an important measure of genetic progression. Rahnenführer et al. (2005) have shown that, for mutagenetic trees, it is a prognostic factor of survival and time to relapse in glioblastoma and prostate cancer patients, respectively, even after adjustment for traditional clinical markers.

Note that because the exponential distributions are memoryless, calculating the waiting time from the wild type will also serve for determining the waiting time between any two patterns. Furthermore, the nature of the conditional factorization for the joint density of X implies that we can restrict attention to the case where $S = P$, i.e., to determining the waiting time until all events have occurred.

Let $S \in J(P)$ be an observable genotype. We define $\text{Exit}(S) = \{j \in P \mid j \notin S, S \cup \{j\} \in J(P)\}$ to be the set of events that have not occurred in S , but could occur next. For any subset $T \subseteq P$, we set $\lambda_T = \sum_{j \in T} \lambda_j$. A chain in the distributive lattice $J(P)$ is a collection of subsets $C_0, C_1, \dots, C_k \in J(P)$ that satisfy $C_i \subset C_{i+1}$ for all i , with all containments strict. A chain is maximal if it is as long as possible. Note that all maximal chains in the distributive lattice $J(P)$ have length $n + 1$ with $n = |P|$ and start with the empty set as C_0 and reach the maximum at $C_n = P$. Let $\mathcal{C}(J(P))$ denote the collection of maximal chains in $J(P)$; a typical element is denoted $C = (C_0, \dots, C_n)$.

Theorem 2.4. *The expected waiting time until all events have occurred is given by the expression*

$$\mathbb{E}[\max_{i \in P} X_i] = \lambda_1 \cdots \lambda_n \sum_{C \in \mathcal{C}(J(P))} \left(\prod_{i=0}^{n-1} \frac{1}{\lambda_{\text{Exit}(C_i)}} \right) \cdot \left(\sum_{i=0}^{n-1} \frac{1}{\lambda_{\text{Exit}(C_i)}} \right).$$

Before proving Theorem 2.4, we want to briefly mention the idea of the proof, because it will be a common technique for proofs throughout the paper. First of all, the indicated expectation involves the integral of a function that depends on maxima, which are not so simple to integrate directly. So the first step is to decompose the integral into a sum of integrals over many different regions (one for each maximal chain in $J(P)$). Over these simpler regions, the maximum function disappears. Furthermore, these regions are each simplicial cones and the integral can then be computed by a simple change of coordinates.

Proof. Let $f(t)$ be the density function from Equation 1. We must compute

$$(2) \quad \int_{\mathbb{R}_{\geq 0}^n} \max_{i \in P} t_i \cdot f(t) dt$$

Let S_n denote the symmetric group on n letters with $\sigma = (\sigma_1, \dots, \sigma_n)$ a typical element. The integral (2) over the positive orthant breaks up as the sum

$$\sum_{\sigma \in S_n} \int_{t_{\sigma_1}=0}^{\infty} \int_{t_{\sigma_2}=t_{\sigma_1}}^{\infty} \cdots \int_{t_{\sigma_n}=t_{\sigma_{n-1}}}^{\infty} t_{\sigma_n} f(t) dt.$$

That is, the sum breaks up the integral into smaller integrals over regions

$$0 < t_{\sigma_1} < t_{\sigma_2} < \cdots < t_{\sigma_n}.$$

The integrand is zero unless $\sigma_1, \sigma_2, \dots, \sigma_n$ is a linear extension of the poset P . In other words, the integrand is zero unless the sets $C_i = \cup_{j=1}^i \{\sigma_j\}$ for $i = 0, \dots, n$ form a maximal chain in the distributive lattice $J(P)$. So suppose that σ is a linear extension of P . Without loss of generality, we may suppose that this linear extension is $1 \prec 2 \prec \cdots \prec n$.

We must compute the integral

$$\int_{t_1=0}^{\infty} \int_{t_2=t_1}^{\infty} \cdots \int_{t_n=t_{n-1}}^{\infty} t_n f(t) dt$$

where over this restricted region, $f(t)$ now has the form

$$f(t) = \prod_{i=1}^n \lambda_i \exp(-\lambda_i(t_i - t_{j(i)}))$$

where $j(i)$ is the largest number with $j(i) \prec i$ in P .

Now introduce the change of coordinates

$$u_0 = t_1, \quad u_i = t_{i+1} - t_i \text{ for } i = 1, 2, \dots, n-1.$$

The determinant of this linear transformation is one, so the integral becomes

$$\int_{u_0=0}^{\infty} \int_{u_1=0}^{\infty} \cdots \int_{u_{n-1}=0}^{\infty} (u_0 + \cdots + u_{n-1}) \prod_{i=1}^n \lambda_i \exp(-\lambda_i(u_{i-1} + u_{i-2} + \cdots + u_{j(i)})) du.$$

The multiple integral is now over a product domain, and involves a function in product form, so we want to break this integral up into the product of integrals. To do this, we must collect the λ_i terms that go with the various u_k terms. In the exponent, we have that λ_i appears as a coefficient of u_k if and only if $i > k \geq j(i)$. This, in turn, implies that when all the events $1, 2, \dots, k$ have occurred, all the predecessor events of i have occurred. But this means that $i \in \text{Exit}(C_k)$, where $C_k = \{1, 2, \dots, k\}$. Thus, the transformed integral breaks up as a sum of n integrals that have the form:

$$\lambda_1 \cdots \lambda_n \cdot \int_{u_0=0}^{\infty} \int_{u_1=0}^{\infty} \cdots \int_{u_{n-1}=0}^{\infty} u_j \prod_{i=0}^{n-1} \exp(-\lambda_{\text{Exit}(C_i)} u_i) du.$$

The integral is over a product domain of a product function. By elementary integration, it is

$$\lambda_1 \cdots \lambda_n \frac{1}{\lambda_{\text{Exit}(C_j)}} \prod_{i=0}^{n-1} \frac{1}{\lambda_{\text{Exit}(C_i)}},$$

which completes the proof. $\square$

3. RELATION TO THE DISCRETE CONJUNCTIVE BAYESIAN NETWORK

In this section, we explore the connection between the CT-CBN and the discrete CBN (D-CBN) introduced in Beerenwinkel et al.. Part of the motivation for this project was to understand how the two types of models relate to each other and how structural information from one model can be used to deduce information about the other. Also, we are naturally led to study discrete models because we rarely have access to the times at which the individual events occurred, but can only check, after a certain sampling time, which of the events have occurred.

We will show that the D-CBN gives a first order approximation to the transition probabilities in the CT-CBN. This suggests that the D-CBN is not optimal from a modeling standpoint as the nature of our applications is to wait until mutations occur. On the other hand, the D-CBN is much simpler to work with, and maximum likelihood estimates for the D-CBN can be used as a first step for iterative algorithms for ML estimation in the censored versions of the CT-CBN, described in Section 4.

To explain the first order approximation result, we consider the CT-CBN as a continuous time Markov chain on the distributive lattice $J(P)$ (see Norris (1997) for background on Markov

chains). The rate matrix for the Markov chain is the upper-triangular $m \times m$ matrix Q , where $m = |J(P)|$. The entries of Q are indexed by pairs of sets of occurred events $S, T \in J(P)$ and are given by

$$Q_{S,T} = \begin{cases} \lambda_j & \text{if } S \subset T \text{ and } T \setminus S = \{j\}, \\ -\lambda_{\text{Exit}(S)} & \text{if } S = T, \text{ and} \\ 0 & \text{otherwise.} \end{cases}$$

If we fix a linear extension of $J(P)$ and order the rows and columns of Q according to this linear extension, Q will be an upper triangular matrix.

Let $p(t)$ be the $m \times m$ matrix where, for $S, T \in J(P)$, the entry $p_{S,T}(t)$ denotes the probability that the continuous time Markov chain with state space $J(P)$, is in state T at time t starting from state S at time 0. This quantity can be calculated by integrating the density function from the continuous time model. However, it is simpler to calculate from standard theory of Markov chains. Indeed, the matrix $p(t)$ is the solution to the system of differential equations

$$\frac{d}{dt}p(t) = Qp(t)$$

subject to the initial conditions $p(0) = I$, the identity matrix. The solution to these first order differential equations is obtained by taking $p(t) = \exp(Qt)$, where $\exp$ denotes the matrix exponential:

$$\exp(Qt) = I + Qt + \frac{Q^2 t^2}{2!} + \frac{Q^3 t^3}{3!} + \cdots.$$

Clearly, the solution to the differential equations then satisfies

$$\frac{d^k}{dt^k}p(t)|_{t=0} = Q^k$$

so a first order approximation to $p(t)$ is a function $\tilde{p}(t)$ that satisfies

$$\tilde{p}(0) = I \quad \text{and} \quad \frac{d}{dt}\tilde{p}(t)|_{t=0} = Q.$$

A first order approximation to the CT-CBN can be derived from the D-CBN as follows. Associated to the D-CBN are n parameters $\theta_1, \dots, \theta_n$, where θ_i is the conditional probability that event i has occurred, given that all its predecessor events have occurred. By setting $\theta_i = 1 - \exp(-\lambda_i t)$ and defining

$$\tilde{p}_{S,T}(t) = \prod_{i \in T \setminus S} \theta_i \prod_{i \in \text{Exit}(T)} (1 - \theta_i), \quad \text{if } S \subseteq T,$$

and $\tilde{p}_{S,T}(t) = 0$ otherwise, the D-CBN is naturally interpreted as a continuous time model, where $\tilde{p}_{S,T}(t)$ is the probability that the D-CBN is in state T at time t given a starting state of S at time 0.

Proposition 3.1. *The model $\tilde{p}(t)$ derived from the D-CBN is a first order approximation to the CT-CBN $p(t)$.*

Proof. Note that diagonal entries of $\tilde{p}(t)$ have the form $\prod \exp(-\lambda_i t)$, and off-diagonal entries are either identically zero or are a product of terms, at least one of which is of the form $1 - \exp(-\lambda_i t)$. This implies that $\tilde{p}(0) = I$.

If $T = S$, then $\tilde{p}_{S,S}(t) = \prod_{i \in \text{Exit}(S)} \exp(-\lambda_i t)$. So, by the product rule

$$\frac{d}{dt} \tilde{p}_{S,S}(t) = \sum_{i \in \text{Exit}(S)} -\lambda_i \tilde{p}_{S,S}(t)$$

and thus $\frac{d}{dt} \tilde{p}_{S,S}(t)|_{t=0} = -\lambda_{\text{Exit}(S)} = Q_{S,S}$. If $S \subset T$ then

$$\tilde{p}_{S,T}(t) = \prod_{i \in T \setminus S} (1 - \exp(-\lambda_i t)) \cdot \prod_{i \in \text{Exit}(T)} \exp(-\lambda_i t)$$

and thus

$$\frac{d}{dt} \tilde{p}_{S,T}(t) = \sum_{i \in T \setminus S} \lambda_i \frac{\exp(-\lambda_i t)}{1 - \exp(-\lambda_i t)} \tilde{p}_{S,T}(t) - \sum_{i \in \text{Exit}(T)} \lambda_i \tilde{p}_{S,T}(t).$$

If $T \setminus S$ has cardinality greater than one, then $\frac{d}{dt} \tilde{p}_{S,T}(t)|_{t=0} = 0 = Q_{S,T}$, since every term in the sum involves at least one expression of the form $1 - \exp(-\lambda_i t)$. On the other hand, if $T = S \cup \{j\}$, then $\frac{d}{dt} \tilde{p}_{S,T}(t)|_{t=0} = \lambda_j = Q_{S,T}$, since only the first term in the sum does not contain an expression of the form $1 - \exp(-\lambda_i t)$. As all other entries in $\tilde{p}(t)$ and Q are zero, this proves that $\tilde{p}(t)$ is a first order approximation to $p(t)$. $\square$

Given that the D-CBN is a first order approximation to the CT-CBN, it seems natural to conjecture that these two models are, in fact, equal to each other. Indeed, if P is the poset with no relations, it is easy to show that these two models coincide. However, if P contains at least one relation, the models are no longer the same, and the D-CBN is not even a second order approximation of the CT-CBN. This is illustrated in the following example.

Example 3.2. Let P be the poset on two elements with one relation $1 \prec 2$ and fix the natural order $\emptyset, \{1\}, \{1, 2\}$ in $J(P)$. If $\lambda_1 \neq \lambda_2$, then

$$\tilde{p}(t) = \begin{pmatrix} e^{-\lambda_1 t} & (1 - e^{-\lambda_1 t})e^{-\lambda_2 t} & (1 - e^{-\lambda_1 t})(1 - e^{-\lambda_2 t}) \\ 0 & e^{-\lambda_2 t} & 1 - e^{-\lambda_2 t} \\ 0 & 0 & 1 \end{pmatrix}$$

and

$$p(t) = \begin{pmatrix} e^{-\lambda_1 t} & \frac{\lambda_1}{\lambda_1 - \lambda_2} (e^{-\lambda_2 t} - e^{-\lambda_1 t}) & 1 - \frac{\lambda_1 e^{-\lambda_2 t} - \lambda_2 e^{-\lambda_1 t}}{\lambda_1 - \lambda_2} \\ 0 & e^{-\lambda_2 t} & 1 - e^{-\lambda_2 t} \\ 0 & 0 & 1 \end{pmatrix}.$$

In particular, $\frac{d^2}{dt^2} \tilde{p}_{\emptyset, \{1\}}(t)|_{t=0} = -\lambda_1^2 - 2\lambda_1 \lambda_2$, whereas $(Q^2)_{\emptyset, \{1\}} = -\lambda_1^2 - \lambda_1 \lambda_2$.

The discrepancies exhibited in the previous example become more dramatic as the poset P develops longer chains. While the D-CBN is not identical to the CT-CBN, its nice properties can be exploited at various points during optimization.

4. CENSORING

Our goal in this section is to define and analyze a censored CT-CBN model that we will apply to genetic data in Section 5. The reason for introducing models with censoring is that we rarely know explicitly the time points $t_1, \dots, t_n$ at which the events have occurred. Often we can only measure, at a particular time, which of the events have occurred so far. It is natural

to assume that the observation times are themselves random. For example, the evolutionary process leading to drug resistance in HIV starts with the onset of therapy. However, the genome of the virus can only be determined after viral rebound, i.e., after loss of viral suppression, which typically involves several mutations. Thus, the sampling time is the time to therapy failure.

We introduce a new event s , such that the random variable X_s is an independent, exponentially distributed stopping time (or sampling time, or observation time), $X_s \sim \text{Exp}(\lambda_s)$. We define a new poset $P_s = P \cup \{s\}$ by adding to the poset of mutations the element s , which has no relations with the other elements in P . In this setting, the events we observe consist of subsets $S \subseteq [n]$, which correspond to the event that $X_i < X_s$ for all $i \in S$ and $X_s < X_i$ for all $i \in [n] \setminus S$.

Thus, an observed set of events S imposes extra relations $i \prec s$ for $i \in S$ and $s \prec i$ for $i \in [n] \setminus S$ on the poset P_s , and we are led to study the poset refinements of P_s . A poset Q is said to refine the poset P_s if every relation in P_s also holds in Q . A realization of the random vector X is said to be compatible with Q , denoted $X \vdash Q$, if $X_i < X_j$ whenever $i \prec j$ in Q . We can directly compute the probability of the event $X \vdash Q$ in terms of the distributive lattices $J(Q)$ and $J(P_s)$. Throughout this section, we abuse notation and say that $X \sim P_s$ if $X = (X_s, X_1, \dots, X_n)$ is distributed according to the CT-CBN associated to poset P_s with parameter vector $\lambda = (\lambda_s, \lambda_1, \dots, \lambda_n)$.

Theorem 4.1. *The probability that $X \sim P_s$ is compatible with the poset Q is given by*

$$(3) \quad \text{Prob}(X \vdash Q) = \lambda_s \lambda_1 \cdots \lambda_n \sum_{C \in \mathcal{C}(J(Q))} \prod_{i=0}^n \frac{1}{\lambda_{\text{Exit}(C_i)}},$$

where the sum runs over all maximal chains in the distributive lattice $J(Q)$.

Remark. Note that in this formula, and in all formulas throughout this section, the expression $\text{Exit}(S)$ always refers to the underlying poset P_s and not to the refinement Q .

Proof. We must compute the integral

$$\int_{\mathbb{R}_{\geq 0}^{n+1}} \mathbb{I}_Q(t) \cdot f(t) dt$$

where $\mathbb{I}_Q(t)$ is the indicator function of compatibility with the poset Q . The integral breaks up into a sum over the linear extensions of the poset Q over regions over the form $t_{\sigma_0} < t_{\sigma_1} < \cdots < t_{\sigma_n}$. Without loss of generality and after renaming the elements of the poset P_s , we can assume that the linear extension of interest is $0 \prec 1 \prec \cdots \prec n$. We must calculate the integral

$$\int_{t_0=0}^{\infty} \int_{t_1=t_0}^{\infty} \cdots \int_{t_n=t_{n-1}}^{\infty} f(t) dt$$

where over the restricted region, the integrand has the form

$$f(t) = \prod_{i=0}^n \lambda_i \exp(-\lambda_i(t_i - t_{j(i)})).$$

Taking the usual change of variables $u_0 = t_0$ and $u_{i+1} = t_{i+1} - t_i$ for $i = 1, \dots, n$ we see that the integral becomes

$$\prod_{i=0}^n \int_{u_i=0}^{\infty} \exp(-\lambda_{\text{Exit}(C_i)} u_i) du_i$$

where $C_i = \{0, 1, \dots, i-1\}$. This yields the desired contribution to the integral. $\square$

Example 4.2. Let P be the poset from Example 2.1 with relations $1 \prec 3$, $2 \prec 3$, and $2 \prec 4$, and consider the extended poset $P_s = P \cup \{s\}$ with no additional relations. Suppose we want to calculate the probability of precisely mutations 2 and 4 occurring before measurement. The refinement $Q_{2,4}$ corresponding to the genotype $\{2, 4\}$ is a chain $2 \prec 4 \prec s \prec 1 \prec 3$, and so the distributive lattice $J(Q_{2,4})$ is also a chain. From Equation 3 we see that

$$\text{Prob}(X \vdash Q_{2,4}) = \lambda_1 \lambda_2 \lambda_3 \lambda_4 \lambda_s \frac{1}{\lambda_1 + \lambda_2 + \lambda_s} \frac{1}{\lambda_1 + \lambda_4 + \lambda_s} \frac{1}{\lambda_1 + \lambda_s} \frac{1}{\lambda_1} \frac{1}{\lambda_3}.$$

On the other hand, the distributive lattice $J(Q_{1,2})$ has four chains and $\text{Prob}(X \vdash Q_{1,2})$ is the sum of four terms of product form. The terms in the sum have common factors, and this expression can be rewritten as

$$\text{Prob}(X \vdash Q_{1,2}) = \frac{\lambda_1 \lambda_2 \lambda_3 \lambda_4 \lambda_s}{(\lambda_1 + \lambda_2 + \lambda_s)(\lambda_3 + \lambda_4 + \lambda_s)(\lambda_3 + \lambda_4)} \left(\frac{1}{\lambda_2 + \lambda_s} + \frac{1}{\lambda_1 + \lambda_4 + \lambda_s} \right) \left(\frac{1}{\lambda_3} + \frac{1}{\lambda_4} \right).$$

The method for building the expression for this probability recursively is explained in Proposition 4.4. $\square$

Given a poset P and a set of parameters $\lambda_1, \dots, \lambda_n$, and λ_s , we obtain a probability distribution $p(P, \lambda) \subseteq \Delta_{2^n}$, the $2^n - 1$ dimensional probability simplex. The set of all such probability distributions is the discrete censored CT-CBN. Although there are $n + 1$ parameters specifying the model, it is easy to see that the family of probability distributions that can arise has dimension n . The loss of dimensionality arises from the fact that $p(P, \lambda) = p(P, t\lambda)$. This is an example of an algebraic statistical model (Pachter and Sturmfels, 2005), since the probability $p(P, \lambda)$ is a rational function of the parameters λ . Unfortunately, these models seem difficult to analyze using techniques from algebraic geometry. Indeed, even the model associated to the poset with no relations, corresponding to independently occurring mutations, lacks a simple description as an algebraic statistical model.

Unlike in the fully observed CT-CBN or the D-CBN, we have found no general closed form expressions for the MLEs of the parameters of the censored CT-CBN. However, as the censored model is a marginalization of the CT-CBN and the CT-CBN is a regular exponential family, we can use the EM algorithm to find ML estimates (see Chapter 8 of Little and Rubin (2002) for a general description of the EM algorithm). While the EM algorithm is only guaranteed to find a local maximum of the likelihood function, our computational experience has been that using exact MLEs from the D-CBN for θ_i and solving for λ_i in the approximate expression $\theta_i = \lambda_i / (\lambda_i + \lambda_s)$ works as a good starting guess for the EM algorithm.

In the EM algorithm for a marginalization of a regular exponential family, we start with a guess for the ML parameters λ^* . Then, given the data, we compute the expected values for the missing sufficient statistics of the fully observed regular exponential family. In our setting, we need to compute, for each $S \subseteq [n]$ that is observed, and for each $i \in [n]$, the expected value

$$(4) \quad \mathbb{E}[X_i - \max_{j \in \text{pa}(i)} X_j \mid X \vdash Q_S].$$

This is the *E-step* of the EM algorithm. The expected sufficient statistics are then used to compute MLEs for λ in the fully observed CT-CBN. This is the *M-step* of the EM algorithm. The EM-algorithm iterates alternations of the E-step and the M-step. After each iteration, the

likelihood function is guaranteed to increase. A fixed point of the EM algorithm must be a critical point of the likelihood function. Running the EM-algorithm with many starting points is a useful heuristic for calculating maximum likelihood estimates.

Since the M-step in our EM algorithm is trivial to calculate from Proposition 2.2, the only thing remaining to compute is the expected value (4). The formula is similar to the one that appears in Theorem 2.4.

Theorem 4.3. *The expected value of $X_i - \max_{j \in \text{pa}(i)} X_j$ given that X is compatible with Q is*

$$\mathbb{E}[X_i - \max_{j \in \text{pa}(i)} X_j | X \vdash Q] = \frac{\lambda_s \lambda_1 \cdots \lambda_n}{\text{Prob}(X \vdash Q)} \sum_{C \subset \mathcal{C}(J(Q))} \left(\left(\prod_{k=0}^n \frac{1}{\lambda_{\text{Exit}(C_k)}} \right) \cdot \left(\sum_{k=0}^n \frac{\iota(i, C_k)}{\lambda_{\text{Exit}(C_k)}} \right) \right)$$

where the first sum is over all maximal chains in $J(Q)$ and

$$\iota(i, C_k) = \begin{cases} 1 & \text{if } i \notin C_k \text{ and } \text{pa}(i) \subseteq C_k \\ 0 & \text{otherwise.} \end{cases}$$

Proof. The proof follows the same basic outline of the proof of Theorem 2.4. The expected value is

$$\mathbb{E}[X_i - \max_{j \in \text{pa}(i)} X_j | X \vdash Q] = \frac{1}{\text{Prob}(X \vdash Q)} \int_{\mathbb{R}_{\geq 0}^{n+1}} (t_i - \max_{j \in \text{pa}(i)} t_j) \cdot \mathbb{I}_Q(t) \cdot f(t) dt.$$

We can calculate the integral by decomposing it into a sum over the linear extensions of Q , i.e., the chains in the distributive lattice $J(Q)$. Without loss of generality, we can suppose that the linear extension is called $0 \prec 1 \prec \cdots \prec n$. For this linear extension, the integral becomes

$$\int_{t_0=0}^{\infty} \int_{t_1=t_0}^{\infty} \cdots \int_{t_n=t_{n-1}}^{\infty} (t_i - t_{j(i)}) f(t) dt$$

and over this region $f(t)$ has the form

$$f(t) = \prod_{k=0}^n \lambda_k \exp(-\lambda_k(t_k - t_{j(k)})).$$

Applying the usual change of coordinates, we can rewrite this integral in product form as

$$\int_{u_0=0}^{\infty} \int_{u_1=0}^{\infty} \cdots \int_{u_n=0}^{\infty} (u_{i-1} + \cdots + u_{j(i)}) \prod_{k=0}^n \lambda_k \exp(-\lambda_k(u_{k-1} + u_{k-2} + \cdots + u_{j(k)})) du.$$

Breaking this integral up as a sum, yields a collection of integrals we have already computed in the proof of Theorem 2.4. However, each term

$$\left(\prod_{k=0}^n \frac{1}{\lambda_{\text{Exit}(C_k)}} \right) \cdot \frac{1}{\lambda_{\text{Exit}(C_k)}}$$

contributes to the sum if and only if $i \in \text{Exit}(C_k)$, i.e., if and only if $\iota(i, C_k) = 1$. $\square$

Rather than computing the expectation from Theorem 4.3 by explicitly listing all maximal chains in the distributive lattice $J(Q)$, the expected value can be computed recursively, by

summing up the distributive lattice. This approach is sometimes referred to as *dynamic programming*. It reduces the computational burden of computing the expectation, because one need not enumerate all the chains in $J(Q)$.

Proposition 4.4. *For each $S \in J(Q)$ define P_S and E_S^i by the formulas*

$$P_S = \sum_{j \in S: S \setminus \{j\} \in J(Q)} \frac{\lambda_j}{\lambda_{\text{Exit}(S \setminus \{j\})}} P_{S \setminus \{j\}}$$

$$E_S^i = \sum_{j \in S: S \setminus \{j\} \in J(Q)} \left(\frac{\lambda_j}{\lambda_{\text{Exit}(S \setminus \{j\})}} E_{S \setminus \{j\}}^i + \iota(i, S \setminus \{j\}) \frac{\lambda_j}{\lambda_{\text{Exit}(S \setminus \{j\})}^2} P_{S \setminus \{j\}} \right),$$

subject to the initial conditions $P_\emptyset = 1$ and $E_\emptyset^i = 0$, where

$$\iota(i, S \setminus \{j\}) = \begin{cases} 1 & \text{if } i \notin S \setminus \{j\} \text{ and } \text{pa}(i) \subseteq S \setminus \{j\} \\ 0 & \text{otherwise.} \end{cases}$$

Then $\text{Prob}(X \vdash Q) = P_{\{s\} \cup [n]}$ and $\mathbb{E}[X_i - \max_{j \in \text{pa}(i)} X_j \mid X \vdash Q] = E_{\{s\} \cup [n]}^i / P_{\{s\} \cup [n]}$.

Proof. Both results follow from writing down a closed form for P_S and E_S^i , proving that these formulas hold inductively, and showing that $P_{\{s\} \cup [n]} = \text{Prob}(X \vdash Q)$ and $\frac{E_{\{s\} \cup [n]}^i}{P_{\{s\} \cup [n]}} = \mathbb{E}[X_i - \max_{j \in \text{pa}(i)} X_j \mid X \vdash Q]$.

To this end, let $Q|_S$ be the induced subposet of Q with element set S . Then

$$P_S = \prod_{i \in S} \lambda_i \sum_{C \in \mathcal{C}(J(Q_S))} \prod_{i=0}^{|S|-1} \frac{1}{\lambda_{\text{Exit}(C_i)}}$$

with $P_\emptyset = 1$. The recurrence

$$P_S = \sum_{j \in S: S \setminus \{j\} \in J(Q)} \frac{\lambda_j}{\lambda_{\text{Exit}(S \setminus \{j\})}} P_{S \setminus \{j\}}$$

is satisfied because every maximal chain in $J(Q|_S)$ comes from a maximal chain in exactly one of the $J(Q|_{S \setminus \{j\}})$ by adding j to the poset $Q|_{S \setminus \{j\}}$ as the last element. Also, $P_{\{s\} \cup [n]}$ has the desired form.

Similarly, it is straightforward to show that

$$E_S^i = \prod_{k \in S} \lambda_k \sum_{C \in \mathcal{C}(J(Q_S))} \left(\left(\prod_{k=0}^{|S|-1} \frac{1}{\lambda_{\text{Exit}(C_k)}} \right) \cdot \left(\sum_{k=0}^{|S|-1} \frac{\iota(i, C_k)}{\lambda_{\text{Exit}(C_k)}} \right) \right)$$

which, together with P_S , above, satisfies the desired recurrence relation. $\square$

5. APPLICATIONS

In this Section, we use the CT-CBN model to describe the accumulation of mutations in four different biological systems (Table 1). The random variables X_i denote the times of fixation of genetic changes in a population of individuals. The definition of a genetic change is different in each example, depending on both the nature of the evolutionary process and the technology

Biological system	Genetic events	#	Samples	Ref.
Prostate cancer	Chromosomal gains and losses	9	54	Rahnenführer et al. (2005)
Colon cancer	Mutated genes	12	35	Sjöblom et al. (2006)
Breast cancer	Mutated genes	9	42	Sjöblom et al. (2006)
HIV drug resistance	Amino acid changes in the HIV RT	7	364	Beerenwinkel et al. (2005a)

TABLE 1. Applications of the CT-CBN model to genetic data. For each biological system (first column), the nature (second column) and the number (third column) of the genetic alterations, the number of observations (fourth column), and a reference pointing to the original study (last column) is shown.

to detect genetic alterations. For all examples, the data is a list of genotypes that have been observed after an unknown sampling time assumed to be exponentially distributed. Thus we apply the censored CT-CBN model. Our goal is to learn the structure of mutational pathways, which is represented by the linear extensions of the CT-CBN defining posets.

Theorem 2.3 states that the structure of the ML CT-CBN model is given by the maximal poset that is compatible with the observed data. In practice, however, the observations are subject to noise, either due to deviations of the data generating process from the model, or due to technical limitations in assessing genetic changes. Thus, for most biomedical data sets, the ML poset will have very few relations, although a large portion of the observations might support more order constraints. We adress this problem following the approach outlined in Beerenwinkel et al. for the discrete CBN.

Consider a family of posets P_ϵ ($0 \leq \epsilon \leq 1$), each of which is maximal with the property that a fraction ϵ of the data is allowed to be incompatible with the poset. We assume that the incompatible genotypes are generated with uniform probability $q_\epsilon = 1/(2^n - |J(P_\epsilon)|)$ and consider the extended model with probabilities

$$\Pr(X_\epsilon \vdash Q \mid \alpha, \lambda) = \begin{cases} \alpha \Pr(X_\epsilon \vdash Q \mid \lambda) & \text{if } Q \text{ refines } P_\epsilon \\ (1 - \alpha) q_\epsilon & \text{else,} \end{cases}$$

where $X_\epsilon \sim P_\epsilon$ and $\alpha = \sum_{g \in J(P_\epsilon)} u_g / \sum_{g \in 2^{[n]}} u_g$ denotes the fraction of the data that are compatible with P_ϵ . The model can also be interpreted as a mixture model with α the ML estimate of the mixing parameter (Beerenwinkel et al., Prop. 8). In the applications, we construct several posets P_ϵ for various values of ϵ and select the poset that maximizes the likelihood of the extended model.

In the first application, we analyze data from comparative genome hybridization (CGH) experiments. This technique detects large scale genomic alterations, namely the gain or loss of chromosome arms, that occur frequently in cancer cells. For example, the event $4q+$ denotes the gain (+) of additional copies of the large (q) arm of chromosome 4. Likewise, $8p-$ refers to the loss (-) of the small arm (p) of chromosome 8. We consider 54 prostate cancer samples, each defined by the presence or absence of the nine alterations $3q+$, $4q+$, $6q+$, $7q+$, $8p-$, $8q+$, $10q-$, $13q+$, and $Xq+$ as defined in Rahnenführer et al. (2005).

In Figure 2, the log-likelihood is shown as a function of the fraction of incompatible genotypes. The poset that maximizes the likelihood explains 89% of the data and is displayed in Figure 3.




FIGURE 2. Maximum likelihood estimation of the discrete censored CT-CBN model for the prostate cancer data. The log-likelihood is displayed as a function of the fraction of data that is incompatible with the poset. The curve has been generated by densely sampling ϵ from the unit interval and estimation of the extended models P_ϵ .




FIGURE 3. Optimal prostate cancer poset corresponding to the maximum in Figure 2. An arrow $p \rightarrow q$ between two genetic events represents the cover relation $p \prec q$ in the Hasse diagram of the poset.

Four of the nine genetic changes do not obey any relation, two events have one predecessor, and

one event occurs only after two parent events have occurred. Note that the second best poset is the empty poset corresponding to $\alpha = 0$.

In our second and third example, we consider mutation data from 35 colon and 42 breast cancer tumors, respectively (Sjöblom et al., 2006). Here, a genetic event is an unspecific mutation in a gene that has been detected by DNA sequencing. Out of the ~ 200 genes identified by Sjöblom et al. (2006) we considered those that were mutated in at least four tumors. For colon cancer, this set comprises *ADAMTSL3*, *APC*, *EPHA3*, *EPHB6*, *FBXW7*, *KRAS*, *MLL3*, *OBSCN*, *PKHD1*, *SMAD4*, *SYNE1*, and *TP53*, while for breast cancer, we identified *ATP8B1*, *CUBN*, *FLJ13479*, *FLNB*, *MACF1*, *OBSCN*, *SPTAN1*, *TECTA*, and *TP53*.




FIGURE 4. ML estimation of the CT-CBN model for the colon cancer data.

The colon cancer ML poset is the empty poset (Figure 4). By contrast, the maximum likelihood breast cancer poset explains 93% of the observations (Figure 5) and consists of three relations (Figure 6). Two of them form the conjunction stating that mutations in both the cubilin gene (*CUBN*) and the obscurin gene (*OBSCN*) occur before the β filamin gene (*FLNB*) is mutated. The third relation identifies tumor protein p53 (*TP53*) as the mutational predecessor of the zinc finger protein 668 (*FLJ13479*). *TP53* is mutated in most colon and breast cancer tumors and known to occur early in the somatic evolution of many cancers.




FIGURE 5. ML estimation of the CT-CBN model for the breast cancer data.



FIGURE 6. Optimal breast cancer poset corresponding to the maximum in .Figure 5.

The last application is concerned with the evolution of drug resistance in HIV. We study the accumulation of amino acid changes in a segment of the HIV *pol* gene that codes for the viral protein reverse transcriptase (RT). The seven resistance-associated mutations 41L, 67N, 69D, 70R, 210W, 215Y, and 219Q (Johnson et al., 2006) are considered, where, for example, 41L indicates the presence of the amino acid leucine (L) at position 41 of the RT. A total of 364 viruses are analyzed that have been isolated from infected patients under therapy with zidovudine, an antiretroviral drug targeting the RT. Amino acid changes have been inferred after DNA sequencing of the *pol* gene.

The optimal poset for the HIV drug resistance data explains 87% of the observations (Figure 7). Its Hasse diagram has two connected components (Figure 8). The first one represents




FIGURE 7. ML estimation of the CT-CBN model for the HIV drug resistance data.




FIGURE 8. Optimal HIV drug resistance poset corresponding to the maximum in .Figure 7.

the linear pathway $215Y \prec 41L \prec 210W$, whereas in the second component mutations $70R$, $67N$, $219Q$, and $69D$, form a rhombus beginning with $70R$ and ending with $69D$. This finding confirms previous studies in which the same clustering of mutations has been described (Beerenwinkel et al., 2005a; Boucher et al., 1992; Larder and Kemp, 1989). The two groups of mutations are often referred to as the “215-41 pathway” and the “70-219 pathway”, respectively. They provide alternative (but not exclusive) routes to resistance for HIV. The CT-CBN model captures this escape behavior and suggests order constraints within each group.

In all applications discussed here, there are several posets with near-optimal performance. Throughout we find these posets to be very similar to the optimal set of relations. For example, the second best HIV drug resistance poset explains 93% of the data and it differs from the optimal one in Figure 8 only in the second component which consists of the two relations $70R \prec 219Q$ and $70R \prec 69D$. Using cross-validation techniques the variation in poset selection or in the selection of individual relations can be studied and may be used to select more robust poset structures.

For each of the four examples, the best mutagenetic trees show inferior performance as compared to the CT-CBN posets. For example, the mutagenetic tree for prostate cancer found in Rahnenführer et al. (2005, Fig. 2) explains only 56% of the data at a log-likelihood of only -248.4 . Unlike mutagenetic trees, CT-CBNs can model the requirement of multiple parent mutations. This type of order constraint was found in three of the four applications considered here.

6. DISCUSSION

Conjunctive Bayesian networks are statistical models for the accumulation of mutations. They are defined by a poset of mutations, which encodes constraints on the order in which mutations can occur. Here we have introduced the CT-CBN, a continuous time version of this model in which each mutation appears after an exponentially distributed waiting time, provided that all predecessor mutations in the poset have already occurred. In an evolutionary process, this waiting time includes the generation of the mutation plus the time it takes for the allele to reach a frequency in the population that allows for its detection. Since we consider only mutations with a selective advantage, the waiting time will be dominated by the mutation process in large populations and by the fixation process in small populations. However, the model does not make any assumptions about the underlying population dynamics. Hence the waiting time is the time to detection of the mutation, which depends on the technology used for measurement. For example, population sequencing of HIV samples can detect mutations with a frequency of at least 20%.

The CT-CBN informs about the order in which mutations tend to occur. For a set of n mutations, the number of possible pathways to evolve the wild type into the type harboring all n mutations is the number of linear extensions of the poset. This cardinality increases rapidly with n , but is hard to compute exactly (Brightwell and Winkler, 1991). However, evolution appears to follow only very few mutational paths to fitter proteins (Weinreich et al., 2006). Thus, we generally expect to find posets with much smaller lattices of order ideals than the full Boolean lattice. Evolution takes place in this reduced genotype space and can be modeled more efficiently.

Estimation of the genetic event poset from observed data helps understanding the phenotypic changes and biological mechanisms responsible for the fitness advantage. Furthermore, the poset allows for identifying early and essential mutational steps that may be predictive of clinical outcome or point to promising drug targets. In cancer research, Fearon and Vogelstein (1990) have proposed linear pathways of genetic alterations as a model of tumorigenesis. These models are known as “Vogelgrams” today (Gatenby and Maini, 2003). The CT-CBN can be regarded as a generalization of the Vogelgram that is equipped with a statistical methodology for model

selection and parameter estimation. In particular, the CT-CBN allows for multiple evolutionary pathways and makes explicit the timeline for the genetic alterations.

We have derived equations for the ML estimates of the model parameters and for the expected waiting time of any genotype. These results are used in the EM algorithm for parameter estimation in the censored model. Censoring is modeled by assuming an exponentially distributed sampling time of the observed genotypes. This model appears most relevant for the data sets available, which often comprise cross-sectional data sampled after different but unknown time periods w.r.t. the evolutionary process. Other censoring schemes might be applicable in the future and could also be worked out. For example, the sampling time (but not the time of appearance of each mutation) can be observed in some situations, giving rise to a different marginalization of the fully observed CT-CBN.

Since model selection relies on a simple combinatorial criterion, and the number of model parameters is only linear in the number of mutations, we expect the CT-CBN to scale well with increasing data sets both in the number of observations and the number of mutations. In the cancer and HIV applications presented here, there are between 7 and 12 genetic events and 35 to 364 observations. It is likely, however, that the number of genes associated with cancer progression, for example, is much higher than currently known (Sjöblom et al., 2006). The running time of the EM algorithm is dominated by the size of the distributive lattice of order ideals. Thus, many mutations can be modeled as long as the number of mutational pathways is limited.

ACKNOWLEDGMENTS

Seth Sullivant was supported by NSF grant DMS-0700078. Part of this work was done while Niko Beerenwinkel was affiliated with the Program for Evolutionary Dynamics at Harvard University and funded by a grant from the Bill & Melinda Gates Foundation through the Grand Challenges in Global Health Initiative.

REFERENCES

- N. Beerenwinkel, M. Däumer, T. Sing, J. Rahnenführer, T. Lengauer, J. Selbig, D. Hoffmann, and R. Kaiser. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. *J Infect Dis*, 191(11):1953–1960, Jun 2005a. doi: 10.1086/430005. URL <http://dx.doi.org/10.1086/430005>.
- N. Beerenwinkel and M. Drton. A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. *Biostatistics*, 8(1):53–71, Jan 2007. doi: 10.1093/biostatistics/kxj033. URL <http://dx.doi.org/10.1093/biostatistics/kxj033>.
- N. Beerenwinkel, N. Eriksson, and B. Sturmfels. Conjunctive Bayesian networks. *Bernoulli*, page In Press. URL <http://arxiv.org/abs/math.ST/0608417>. <http://arxiv.org/abs/math.ST/0608417>.
- N. Beerenwinkel, N. Eriksson, and B. Sturmfels. Evolution on distributive lattices. *J Theor Biol*, 242(2):409–420, Sep 2006. doi: 10.1016/j.jtbi.2006.03.013. URL <http://dx.doi.org/10.1016/j.jtbi.2006.03.013>.

- N. Beerenwinkel, J. Rahnenführer, M. Däumer, D. Hoffmann, R. Kaiser, J. Selbig, and T. Lengauer. Learning multiple evolutionary pathways from cross-sectional data. *J Comput Biol*, 12(6):584–598, 2005b. doi: 10.1089/cmb.2005.12.584. URL <http://dx.doi.org/10.1089/cmb.2005.12.584>. RECOMB 2004.
- N. Beerenwinkel, J. Rahnenführer, R. Kaiser, D. Hoffmann, J. Selbig, and T. Lengauer. Mtreemix: a software package for learning and using mixture models of mutagenetic trees. *Bioinformatics*, 21(9):2106–2107, May 2005c. doi: 10.1093/bioinformatics/bti274. URL <http://dx.doi.org/10.1093/bioinformatics/bti274>.
- C. A. Boucher, E. O’Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. Lange, J. Goudsmit, and B. A. Larder. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. *J Infect Dis*, 165(1):105–110, Jan 1992.
- G. R. Brightwell and P. Winkler. Counting linear extensions. *Order*, 8:225–242, 1991.
- Z. L. Brumme, C. J. Brumme, D. Heckerman, B. T. Korber, M. Daniels, J. Carlson, C. Kadie, T. Bhattacharya, C. Chui, J. Szinger, T. Mo, R. S. Hogg, J. S. G. Montaner, N. Frahm, C. Brander, B. D. Walker, and P. R. Harrigan. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. *PLoS Pathog*, 3(7):e94, Jul 2007. doi: 10.1371/journal.ppat.0030094. URL <http://dx.doi.org/10.1371/journal.ppat.0030094>.
- K. Deforche, T. Silander, R. Camacho, Z. Grossman, M. A. Soares, K. V. Laethem, R. Kantor, Y. Moreau, A.-M. Vandamme, and non B. Workgroup. Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. *Bioinformatics*, 22(24):2975–2979, Dec 2006.
- R. Desper, F. Jiang, O. P. Kallioniemi, H. Moch, C. H. Papadimitriou, and A. A. Schäffer. Inferring tree models for oncogenesis from comparative genome hybridization data. *J Comput Biol*, 6(1):37–51, 1999.
- E. R. Fearon and B. Vogelstein. A genetic model for colorectal tumorigenesis. *Cell*, 61(5):759–767, Jun 1990.
- A. Foulkes and V. DeGruttola. Characterizing the progression of viral mutations over time. *J Am Stat Assoc*, 98(464):859–867, 2003.
- R. A. Gatenby and P. K. Maini. Mathematical oncology: cancer summed up. *Nature*, 421(6921):321, Jan 2003. doi: 10.1038/421321a. URL <http://dx.doi.org/10.1038/421321a>.
- M. Hjelm, M. Hglund, and J. Lagergren. New probabilistic network models and algorithms for oncogenesis. *J Comput Biol*, 13(4):853–865, May 2006. doi: 10.1089/cmb.2006.13.853. URL <http://dx.doi.org/10.1089/cmb.2006.13.853>.
- V. A. Johnson, F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. Update of the drug resistance mutations in hiv-1: Fall 2006. *Top HIV Med*, 14(3):125–130, 2006.
- B. A. Larder and S. D. Kemp. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). *Science*, 246(4934):1155–1158, Dec 1989.
- J. Little and D. Rubin. *Statistical Analysis with Missing Data*. John Wiley & Sons, Hoboken, NJ, 2002.
- J. Norris. *Markov Chains*. Cambridge University Press, 1997.

- L. Pachter and B. Sturmfels, editors. *Algebraic Statistics for Computational Biology*. Cambridge University Press, Cambridge, UK, 2005. doi: 10.2277/0521857007.
- M. D. Radmacher, R. Simon, R. Desper, R. Taetle, A. A. Schäffer, and M. A. Nelson. Graph models of oncogenesis with an application to melanoma. *J Theor Biol*, 212(4):535–548, Oct 2001. doi: 10.1006/jtbi.2001.2395. URL <http://dx.doi.org/10.1006/jtbi.2001.2395>.
- J. Rahnenführer, N. Beerenwinkel, W. A. Schulz, C. Hartmann, A. von Deimling, B. Wullich, and T. Lengauer. Estimating cancer survival and clinical outcome based on genetic tumor progression scores. *Bioinformatics*, 21(10):2438–2446, May 2005. doi: 10.1093/bioinformatics/bti312. URL <http://dx.doi.org/10.1093/bioinformatics/bti312>.
- R. Simon, R. Desper, C. H. Papadimitriou, A. Peng, D. S. Alberts, R. Taetle, J. M. Trent, and A. A. Schäffer. Chromosome abnormalities in ovarian adenocarcinoma: Iii. using breakpoint data to infer and test mathematical models for oncogenesis. *Genes Chromosomes Cancer*, 28(1):106–120, May 2000.
- T. Sjöblom, S. Jones, L. D. Wood, D. W. Parsons, J. Lin, T. D. Barber, D. Mandelker, R. J. Leary, J. Ptak, N. Silliman, S. Szabo, P. Buckhaults, C. Farrell, P. Meeh, S. D. Markowitz, J. Willis, D. Dawson, J. K. V. Willson, A. F. Gazdar, J. Hartigan, L. Wu, C. Liu, G. Parmigiani, B. H. Park, K. E. Bachman, N. Papadopoulos, B. Vogelstein, K. W. Kinzler, and V. E. Velculescu. The consensus coding sequences of human breast and colorectal cancers. *Science*, 314(5797):268–274, Oct 2006. doi: 10.1126/science.1133427. URL <http://dx.doi.org/10.1126/science.1133427>.
- R. Stanley. *Enumerative Combinatorics*. Cambridge University Press, 1999.
- A. von Heydebreck, B. Gunawan, and L. Fzesi. Maximum likelihood estimation of oncogenetic tree models. *Biostatistics*, 5(4):545–556, Oct 2004. doi: 10.1093/biostatistics/kxh007. URL <http://dx.doi.org/10.1093/biostatistics/kxh007>.
- D. M. Weinreich, N. F. Delaney, M. A. Depristo, and D. L. Hartl. Darwinian evolution can follow only very few mutational paths to fitter proteins. *Science*, 312(5770):111–114, Apr 2006. doi: 10.1126/science.1123539. URL <http://dx.doi.org/10.1126/science.1123539>.

DEPARTMENT OF BIOSYSTEMS SCIENCE AND ENGINEERING, ETH ZURICH, MATTENSTRASSE 26, CH-4058 BASEL, SWITZERLAND

E-mail address: niko.beerenwinkel@bsse.ethz.ch

DEPARTMENT OF MATHEMATICS AND SOCIETY OF FELLOWS, HARVARD UNIVERSITY, CAMBRIDGE, MA 02138

E-mail address: seths@math.harvard.edu